During his more than ten years at Cabot, Michael Cintolo has uncovered exceptional growth stocks and helped to create new tools and rules for buying and selling stocks. Perhaps most notable was his development of the proprietary trend-following market timing system, Cabot Tides, which has helped Cabot place among the top investment newsletters numerous times. Cabot Growth Investor has been consistently recognized for outstanding performance by Hulbert Financial Digest and Timer Digest. It is one of Hulbert's top five newsletters for five-year risk-adjusted performance with a 13.2% annualized return as of June 30, 2011. It is also ranked among the Top Ten Newsletters by Timer Digest for long-term performance.
We’re usually not big on one-drug biotech firms, as any hint of competition or a raised eyebrow from regulators can cause the stock to tumble — but Intra-Cellular Therapies (ITCI) could be the exception, suggests Mike Cintolo, editor of Cabot Top Ten Trader.
Halozyme (HALO) has been the top stock on our watch list for a few weeks now, and while it’s not immune to the market’s wiggles, the stock has actually been rounding out a big launching pad as the indexes implode, observes Mike Cintolo, editor of Cabot Growth Investor.
As the oil rally matures, we’re likely to see more secondary-type names kick into gear — not real leaders, but firms that are thriving in today’s high-price environment, observes Mike Cintolo, editor of Cabot Top Ten Trader.
The video game industry is slowing after a meteoric boom at the start of the pandemic, with some game makers reporting weaker sales and a declining user base this year, explains Mike Cintolo, editor of Cabot Top Ten Trader.